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a  b  s  t  r  a  c  t
Fibromyalgia (FM) and hyperparathyroidism may present similar symptoms (muscu-
loskeletal pain, cognitive disorders, insomnia, depression and anxiety), causing diagnostic
confusion.
Objectives: To determine the frequency of asymptomatic hyperparathyroidism in a sample
of  patients with FM and to evaluate the association of laboratory abnormalities to clinical
symptoms.
Methods: Cross-sectional study with 100 women with FM and 57 healthy women (compari-
son  group). Parathyroid hormone (PTH), calcium and albumin levels were accessed, as well
as  symptoms in the FM group.
Results: In FM group, mean serum calcium (9.6 ± 0.98 mg/dL) and PTH (57.06 ± 68.98 pg/mL)
values were considered normal, although PTH levels had been signiﬁcantly higher than in
the  comparison group (37.12 ± 19.02 pg/mL; p = 0.001). Hypercalcemic hyperparathyroidism
was  diagnosed in 6% of patients with FM, and 17% of these women exhibited only high lev-
els  of PTH, featuring a normocalcemic hyperparathyroidism, with higher frequencies than
those  expected for their age. There was no signiﬁcant association between hyperparathy-
roidism and FM symptoms, except for epigastric pain, which was more frequent in the group
of  patients concomitantly with both diseases (p = 0.012).
Conclusions: A high frequency of hyperparathyroidism was noted in women with FM versus
the  general population. Normocalcemic hyperparathyroidism was also more frequent in
patients with FM. Longitudinal studies with greater number of patients are needed to assess
whether this is an association by chance only, if the increased serum levels of PTH are part ofFM  pathophysiology, or even if these would not be cases of FM, but of hyperparathyroidism.
©  2016 Published by Elsevier Editora Ltda. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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255-5021/© 2016 Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://
reativecommons.org/licenses/by-nc-nd/4.0/).
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Frequência  elevada  de  hiperparatireoidismo  assintomático  em  pacientes
com  ﬁbromialgia:  associac¸ão  ao  acaso  ou  erro  diagnóstico?
Palavras-chave:
Fibromialgia
Hiperparatireoidismo
Dor musculoesquelética
Hipercalcemia
r  e  s  u  m  o
A ﬁbromialgia (FM) e o hiperparatireoidismo podem apresentar sintomas semelhantes
(dores osteomusculares, distúrbios cognitivos, insônia, depressão e ansiedade) e causar
confusão diagnóstica.
Objetivos: Determinar a frequência de hiperparatireoidismo assintomático em uma  amostra
de  pacientes com FM e avaliar a associac¸ão das alterac¸ões laboratoriais com a sintomatolo-
gia.
Metodologia: Estudo transversal com 100 mulheres portadoras de FM e 57 mulheres saudáveis
(grupo de comparac¸ão). Foram pesquisados os níveis de paratormônio (PTH), cálcio e albu-
mina, além da pesquisa de sintomas no grupo com FM.
Resultados: No grupo com FM, os valores médios de cálcio sérico (9,6 ± 0,98 mg/dL) e de PTH
(57,06 ± 68,98pg/mL) foram considerados normais, embora os níveis de PTH tivessem sido
signiﬁcativamente maiores do que no grupo de comparac¸ão (37,12 ± 19,02 pg/mL; p = 0,001).
O  hiperparatireoidismo hipercalcêmico foi diagnosticado em 6% das pacientes com FM e 17%
delas apresentaram apenas PTH elevado, o que caracterizou o hiperparatireoidismo normo-
calcêmico, frequências maiores do que esperada para a faixa etária. Não houve associac¸ão
signiﬁcativa entre hiperparatireoidismo e sintomas da FM, com excec¸ão da epigastralgia,
que foi mais frequente no grupo de pacientes com as duas doenc¸as concomitantes (p = 0,012).
Conclusões: Houve frequência elevada de hiperparatireoidismo em portadoras de FM quanto
à  populac¸ão geral. Hiperparatireoidismo normocalcêmico também foi mais frequente em
pacientes com FM. Estudos longitudinais e com maior número de pacientes são necessários
para avaliar se trata-se apenas de uma associac¸ão ao acaso, se as elevac¸ões séricas do
PTH  fazem parte da ﬁsiopatologia da FM ou, ainda, se não seriam casos de FM,  e sim de
hiperparatireoidismo.
©  2016 Publicado por Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma
c¸a  Clicen
Introduction
Primary hyperparathyroidism (PHP), a disease caused by a
hyperactive parathyroid and consequent hypercalcemia, is
associated in 85–90% of cases, to the presence of solitary gland
adenomas, occurring most commonly in people aged over 50
and in women in post-menopause, with a prevalence of 0.78%
for the general population. Although the clinical presentation
is variable, the asymptomatic hypercalcemia form is the most
common (50–80%).1,2
Fibromyalgia (FM) is one of the most common rheumatic
disorders, affecting approximately 2–8% of the popula-
tion, depending on the diagnostic criteria used for its
classiﬁcation.3 FM affects specially young women  (30–55 years
old),4 but with the use of new classiﬁcation criteria,5 the preva-
lence in men  has increased.6 Its main feature is a diffuse
and chronic musculoskeletal pain associated with symptoms
such as fatigue, sleep disturbances, morning stiffness, diffuse
paresthesias, a subjective feeling of edema, cognitive disor-
ders, depression and anxiety.7 The cause of FM is unknown,
but its development is associated with a disorder of cen-
tral nervous system regulation with respect to pain. So far,
no signiﬁcant laboratory abnormalities were identiﬁed in FM
patients.8
Fatigue, arthralgia, myalgia, sleep disturbances, depres-
sion, anxiety and memory  impairment – common symptomsC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
in patients with FM – are part of the nonspeciﬁc symptoms
in patients with PHP. Asymptomatic PHP is understood as
that case in which laboratory changes are occurring, with ele-
vated serum levels of parathyroid hormone (PTH) and calcium,
without the presence of the classic manifestations of PHP,
for instance, severe hypercalcemia, cystic ﬁbrous osteitis and
advanced kidney disease.2 Starting in the 70s, with the acqui-
sition of new knowledge and with improved techniques for the
determination of calcium and PTH, it was observed that PHP
is a common disorder, and usually has no serious or speciﬁc
symptoms.2 In a series of 124 cases of PHP evaluated in the city
of Recife (Brazil), 47% had no symptoms related to the disease,
while 25% suffered from cystic ﬁbrous osteitis, 25% exhibited
kidney stones without bone involvement, and 2% presented
with typical neuropsychiatric syndrome.9
Another study involving 4207 patients aged over 18 in pub-
lic and private endocrinology centers in Recife (Brazil), found
a prevalence of 0.78% (95% CI, 0.52 to 1.04) of PHP, of which
81.8% were asymptomatic.10 The ratio between women:men
was 7.2:1, the mean age was 61 ± 16 years and 89.7% of affected
females were postmenopausal. Among the typical manifes-
tations of PHP, ﬁbrous osteitis was present in 6.1% of cases,
nephrolithiasis in 18.2%, and acute neuropsychiatric syn-
drome in 3%. The prevalence of nonspeciﬁc symptoms was
51.5% for fatigue and 39.3% for muscle weakness.10
A former study also conducted in Recife (Brazil) determined
a prevalence of 1.3% of PHP in postmenopausal women. Of
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his total, 50% of the cases presented in a form considered as
symptomatic, characterized by nonspeciﬁc symptoms such
s fatigue, arthralgia, myalgia and sleep disorders.11
In patients with asymptomatic PHP, a rise in serum levels
f calcium is found, but usually only 1 mg/dL above the upper
imit of normal. In general, PTH levels are 1.5–2.0 times greater
han the upper limit of normal, while the 24-hour urinary cal-
ium tends to remain unchanged.12
Similar to FM,  hyperparathyroidism also predominates in
omen, but in a little older age group (post-menopausal
emales), increasing in prevalence with age.13,14 Despite the
imilarity between symptoms of FM and asymptomatic hyper-
arathyroidism, there are few publications evaluating this
ssociation. This study aimed to determine the frequency of
symptomatic hyperparathyroidism in women with FM, ver-
fy the association with clinical parameters, and compare the
esults of PTH and calcium found in healthy women.
ethodology
atients
 cross-sectional, descriptive study was conducted between
ugust 2011 and January 2012, and a total of 100 subjects
rom the Fibromyalgia Outpatient Clinic of the Rheumato-
ogy Department of the Hospital das Clinicas, Universidade
ederal de Pernambuco (HC-UFPE) were included. For admis-
ion to the study, the participants should be 20–55-year old
omen and meet the criteria for classiﬁcation and diagnosis
f FM (FM Group) according to the American College of Rheu-
atology (ACR), respectively from 1990 and 2010.5,15 Patients
ho  refused to sign the consent form and those with a previ-
us diagnosis of malignancy, bone metastases, granulomatous
nd/or infectious diseases, kidney disease, hyperthyroidism,
ypothyroidism, and acromegaly, in addition to patients who
ere taking thiazide diuretics, lithium salts or in replacement
herapy with calcium and vitamin D were excluded. Patients
lder than 55 years were also excluded to avoid a selection
ias, since PHP is more  common in this age group.
Apart from this group, samples of 57 healthy women were
lso collected, which formed the comparison group. Matched
or age, the criteria for inclusion and exclusion of this group
ere the same to the study group, except for the diagnosis of
M.
linical  and  laboratory  evaluation
he data collection protocol was always applied by the same
esearcher during an outpatient consultation; and informa-
ion necessary for the study was acquired directly with the
atient and supplemented by a review of her medical record.
t the end of the consultation, blood was collected for serum
alcium, albumin and PTH (intact molecule) determination.
he amount of serum calcium was obtained using an auto-
nalyzer (ARCHITECT c Systems, Abbott, USA) whose adopted
eference values range from 8.6 to 10.3 mg/dL with a 0.4 mg/dL
etection limit. For the dosage of PTH a chemoilluminomet-
ic assay (IMMULITE 2000 DPC, Los Angeles, USA) was used,
ith reference values of 12–69 pg/mL and analytical sensitivity 6;5 6(5):391–397 393
(lower detection limit which can be distinguished from zero) of
3.0 pg/mL. To serum albumin dosage, bromocresol dye, which
speciﬁcally binds to albumin forming a colored complex, was
used. The reference values vary from 3.2 to 5.2 g/dL, with
a detection limit of 0.3 g/dL (ARCHITECT c Systems, Abbott,
USA). In the presence of hypoalbuminemia (values <3.2 g/dL),
serum calcium was corrected by following formula16:
Corrected calcium (mg/dL)  = Total calcium (mg/dL)
+ 0.8 × [4 − albumin (g/dL)]
All samples were processed in the HC-UFPE Laboratory. The
study was approved by the Human Research Ethics Committee
in the Health Sciences Center of UFPE and all study subjects
signed an informed consent prior to having their data and
blood samples collected.
Deﬁnition  of  variables
The variables evaluated in the study were deﬁned as follows:
• Depression:  a subjective feeling of sadness diagnosed by a
psychiatrist or treatment with speciﬁc medications
• Fatigue: easy tiredness, lethargy without clinical signs to jus-
tify another speciﬁc disease
• Myalgia: muscle pain anywhere in the body
• Arthralgia: non-inﬂammatory, painful joint symptoms
• Emotional lability: depressive symptoms, anxiety, apprehen-
sion, irritability or nervousness
• Headache: any pain that occurs in one or more  skull areas
• Non-restorative sleep: feeling tired upon waking
• Changes in memory: forgetting situations, difﬁculty concen-
trating on activities
• Hyperparathyroidism: hypercalcemia (calcium >10.3 mg/dL)
and elevated PTH values (PTH >69 pg/mL)
• Normocalcemic hyperparathyroidism: high PTH (PTH
>69 pg/mL) with normal levels of serum calcium.
Statistics
All tests were applied with a 95% conﬁdence interval. The
numeric variables are represented by measures of central ten-
dency and dispersion measures. The Kolmogorov–Smirnov
normality test for quantitative variables was used. To verify
the existence of an association, Fisher’s exact test for cate-
gorical variables and for comparison of two groups (Student t
[normal distribution] and Mann–Whitney [non-normal distri-
bution] test) was used. For statistical calculations, the software
SPSS (Statistical Package for Social Sciences), version 17, was used.
Results
Among the total of 157 women who had their data col-
lected, 100 were diagnosed with ﬁbromyalgia and 57 were
healthy. The mean (± SD) age of the patients with FM was 42.4
(± 8.42) years. As can be seen in Table 1, the mean values of cal-
cium and PTH in patients with FM were within normal limits;
however, PTH levels in the FM group were signiﬁcantly higher
versus comparison group (p = 0.001).
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Table 1 – Distribution of means for age, serum calcium
and parathyroid hormone in ﬁbromyalgia and
comparison groups.
Variables Groups p-Value
FM Comparison
Mean ± SD Mean ± SD
Age (years) 42.4 ± 8.42 41.3 ± 9.4 0.443a
Calcium (mg/dL) 9.6 ± 1.0 9.5 ± 0.3 0.612b
PTH (pg/mL) 57.1 ± 69.0 37.1 ± 19.0 0.001b
FM, ﬁbromyalgia; SD, standard deviation; PTH, parathyroid
hormone.
a Student’s t test.
Table 3 – Frequency of clinical symptoms of patients in
ﬁbromyalgia group, with and without
hyperparathyroidism.
Variables FM group p-Valuea
With HP Without HP
n (%) n (%)
Arthralgia 6 (100) 85 (90.4) 1.000
Myalgia 6 (100) 86 (91.5) 1.000
Headache 6 (100) 80 (85.1) 0.591
Depression 2 (33.3) 35 (37.2) 1.000
Fatigue 5 (83.3) 82 (87.2) 0.576
Non-restorative sleep 6 (100) 84 (89.4) 1.000
Memory change 5 (83.3) 66 (70.2) 0.669
Nausea/vomiting 3 (50) 44 (46.8) 1.000
Epigastric pain 6 (100) 43 (45.5) 0.012
Constipation 0 (0) 16 (17) 0.586
TMA pain 1 (16.7) 21 (22.3) 1.000
Urinary changes 0 (0) 16 (17) 0.586
FM, ﬁbromyalgia; HP, hyperparathyroidism; TMA, temporo-
mandibular joint.
a Fisher’s exact test.b Mann–Whitney test.
According to the criteria for deﬁning hypercalcemic hyper-
parathyroidism, it was possible to diagnose the disease in six
patients (6% frequency) with FM.  No woman in comparison
group had a diagnosis of PHP; but this difference was not
statistically signiﬁcant (p = 0.087). However, the frequency of
normocalcemic hyperparathyroidism in FM patients was 17%
in the FM group versus 5.2% in comparison group, with statis-
tical signiﬁcance (p = 0.045) (Table 2).
The prevalence of the most common symptoms of these
two conditions was similar in FM women with and with-
out hyperparathyroidism (Table 3). Except for epigastric pain
(p = 0.012), no other symptoms were signiﬁcantly associated
with the presence of hyperparathyroidism.
Discussion
In our study, we observed a higher frequency of asymp-
tomatic normocalcemic and hypercalcemic hyperparathy-
roidism (although not statistically signiﬁcant for the latest
manifestation) in patients with ﬁbromyalgia, when compared
to the group of healthy women. The frequency of 6% of hyper-
parathyroidism found in our sample of patients with FM is also
higher than that expected for this age-matched population, as
well as for the older population. In the general population, the
prevalence of hyperparathyroidism for all ages is 0.3–0.5%.17,18A study in the city of Recife, Brazil showed a prevalence of
0.78%, and the vast majority (81.8%) were postmenopausal
women.10 Although we have not conducted a prevalence
Table 2 – Frequency of hyperparathyroidism and
normocalcemic hyperparathyroidism in ﬁbromyalgia
and comparison groups.
Group p-Valuea
FM (n = 100) Comparison (n = 57)
n (%) n (%)
Hypercalcemic HP 6 (6.0) 0 (0.0) 0.087
Normocalcemic HP 17 (17.0) 3 (5.2) 0.045
HP, hyperparathyroidism; FM, ﬁbromyalgia.
a Fisher’s exact test.study with a large number of patients, our data indi-
cate a higher frequency of hyperparathyroidism in patients
with FM.
Another phenotype of hyperparathyroidism has been
described, consisting of patients with normal serum calcium
and with PTH elevation in the absence of other known cause
for this hormonal increase: the normocalcemic hyperparathy-
roidism. It has been proposed that this entity would be the ﬁrst
phase of a biphasic disease, that later would become a case
of hyperparathyroidism.19 There are few population-based
studies and the prevalence of normocalcemic hyperparathy-
roidism is not well established, although it may be between
0.4 and 3.1%. Normocalcemic hyperparathyroidism should
be considered as part of the diagnostic spectrum of hyper-
parathyroidism, and such patients should be monitored with
periodic laboratory determinations, with the aim of an early
detection of hypercalcemia.19 In our sample, the frequency of
normocalcemic hyperparathyroidism was even higher (17%)
than that for hypercalcemic hyperparathyroidism (6%), with a
statistical difference in relation to the presence of this con-
dition, when these ﬁndings were compared with those of
healthy women. However, it would be necessary to obtain
serum levels of vitamin D to assess its effect on calcium lev-
els, which was not possible for this study, and this is its main
limitation.
Currently, asymptomatic hypercalcemia is considered the
most common form of presentation of PHP.20 However, some
studies have shown that, in fact, these patients exhibit symp-
toms, but because of its insidious and non-speciﬁc nature,
these are not initially assigned speciﬁcally to PHP.12,21 In
a sample of 229 patients with PHP and with surgical indi-
cation, seen during a 15-month period, the most frequent
symptoms were fatigue, asthenia, arthralgia, impaired con-
centration and memory,  anxiety and depression.22 In view of
this context, the clinical presentation of PHP becomes similar
to the picture presented by patients with FM,23 requiring the
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ompletion of laboratory tests to distinguish these two clinical
ntities.
Although these speciﬁc symptoms are quite frequent in
atients with hyperparathyroidism, its etiology and relation-
hip to speciﬁc laboratory abnormalities are still unknown.
lthough there is an improvement in symptoms after com-
letion of parathyroidectomy,24 it is unclear whether these
ymptoms are mediated by hypercalcemia, the elevation of
TH, or by some other unknown mechanism.22 The cor-
elation between the normalization of laboratory ﬁndings
nd the resolution of a large number of symptoms after
he parathyroidectomy suggests that the symptoms associ-
ted with hyperparathyroidism are mediated by laboratory
iochemical abnormalities.22 Bargren et al. assessed if the
everity of symptoms is related to serum calcium and PTH lev-
ls. It was unexpectedly observed that the majority of patients
ith bone or joint pain, depression, constipation and renal cal-
uli had serum calcium levels <11.2 mg/dL, and there was no
ssociation of symptoms with PTH levels.22 In our study, a rela-
ionship between PTH or calcium levels with the symptoms
as also not found.
Vitamin D deﬁciency can occur in patients with FM,25 but
he results found in the literature are conﬂicting.26–28 Cur-
ently, it is not known whether low serum levels of vitamin
 could be part of the pathophysiology of the generation and
aintenance of chronic pain, or a consequence of less mobil-
ty or of depressive symptoms leading to a lower sun exposure,
r also of high rates of adiposity that decrease vitamin D
ynthesis.29 A study published in 2010 and carried out in order
o evaluate serum levels of vitamin D in patients with FM
ersus healthy controls, noted that there was no difference
etween the two groups, but the levels of PTH were signiﬁ-
antly higher in patients with FM (59.9 ± 17.6 pg/L) than in the
omparison group (48.5 ± 17.4 pg/L) (p = 0.014); in this study a
elation between PTH levels and clinical symptoms was not
valuated.30
An interesting study in 2014 evaluated the presence
f FM in hemodialysis patients, ﬁnding a frequency of
2.2%. Among patients with and without FM, there was no
ifference between epidemiological or clinical parameters
elated to dialysis. Also, there was no signiﬁcant differ-
nce in laboratory parameters between the groups, except
or PTH levels, which were higher in patients with FM
p = 0.002).31
Ferrari and Russell determined the prevalence of PHP in
 sample of patients with FM,  in patients with diffuse pain
ho  did not meet criteria for FM,  and in a group of patients
ith localized musculoskeletal pain. A prevalence of about 6%
f PHP was found in these three groups – a result similar to
urs, and which represents an index higher than that observed
n the general population. The result of this study suggests
he possibility of an association between PHP and diffuse or
ocalized musculoskeletal pain.32
Several authors cite hyperparathyroidism as a differential
iagnosis of musculoskeletal diseases, and there are reports in
he literature of cases of PHP mistakenly diagnosed as FM.33–35n addition, among patients with symptoms of FM and PHP
ho  underwent parathyroidectomy, 89% had improvement of
ymptoms of FM,  and 77% and 21% decreased or discontinued,
espectively, medications used for this purpose.34 6;5 6(5):391–397 395
In our study, none of the clinical symptoms similar to
the two diseases, such as arthralgia, myalgia, non-restorative
sleep, memory  changes and depression was different between
patients with FM with and without hyperparathyroidism,
except in the case of epigastric pain, which was signiﬁcantly
more frequent in patients with increased PTH and calcium.
Gastrointestinal manifestations of hyperparathyroidism are
recognized for several decades, and may even be the initial iso-
lated symptom.36,37 Among the most common symptoms one
can observe constipation (33%), epigastric pain (30%), nausea
(24%) and loss of appetite (15%), with a signiﬁcant reduc-
tion of these symptoms after parathyroidectomy.38 The exact
pathophysiological mechanism of these changes is not fully
understood, but it is believed that atony of the gastrointesti-
nal tract occurs as a result of the sustained stimulation of the
PTH receptor, which would lead to constipation in the colon
and to dyspepsia in the stomach.39 Thus, perhaps the epigas-
tric pain or other unexplained and persistent gastrointestinal
symptoms may constitute an indicator for studies on PHP in
patients with FM.
The main limitation of this study was the absence of
results of vitamin D dosage in our population. In PHP, the
most likely cause of unusually low concentrations of vita-
min  D is the increased metabolic clearance induced by
1.25(OH)2D, and possibly by PTH, since the levels of 25(OH)D
return to normal after parathyroidectomy.19 However, the
assessment of vitamin D was not performed in our compar-
ison group, although we  found signiﬁcant differences in the
frequency of normocalcemic hyperparathyroidism between
groups.
Our study set out to be a preliminary assessment of an asso-
ciation between hyperparathyroidism and FM.  According to
our results and the few data in the literature, apparently such
association exists. But longitudinal studies with larger num-
bers of patients and controls and with an evaluation of serum
levels of vitamin D are needed to conﬁrm whether this is only
a chance association, if the increased serum PTH are part of
the FM pathophysiology, or if these actually would not be cases
of FM, but of asymptomatic PHP.
Hyperparathyroidism, despite having symptoms similar to
FM, has different evolution and prognosis, which may progress
to higher morbidity and major clinical complications that can
be prevented with an early diagnosis. Although most patients
with asymptomatic hyperparathyroidism present a stable dis-
ease, about 25% show evidence of progression of the disease
during follow-up, indicating that it is important to monitor
patients not subjected to parathyroidectomy.24
Thus, based on these results found, the request of a lab-
oratory evaluation of calcium and PTH serum levels may be
suggested in the evaluation of patients with FM and, in case
of any change, one must continue the investigation in search
of PHP. However, further studies with greater statistical power
may conﬁrm the association of the two diseases and provide
better subsidies for routine assessment of the parathyroid
glands in patients with FM.Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
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